Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627237 | 0.86 | PIK3CA (0.60) | PIK3CAKDM4EHSD17B10GRIA2GRIA4 | |
| SCHEMBL623010 | 0.85 | PIK3CA (0.50) | PIK3CAALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL17244477 | 0.85 | PIK3CA (0.47) | PIK3CAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3401685 | 0.84 | PIK3CA (0.49) | PIK3CAALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL3403839 | 0.84 | PIK3CA (0.51) | PIK3CAALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL623815 | 0.84 | PIK3CA (0.47) | PIK3CAALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL3404260 | 0.77 | PIK3CA (0.65) | PIK3CAALDH1A1GRIA2GRIA4PIK3R1 | |
| SCHEMBL624130 | 0.75 | KDM4E (0.47) | PIK3CAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL8010176 | 0.75 | PIK3CA (0.56) | PIK3CAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3425682 | 0.75 | PIK3CA (0.61) | PIK3CAALDH1A1KDM4EHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2250160-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325925-A1 | Thiophenes and uses thereof | PIK3CA, JAK2, MTOR | PIK3CA 1/4885ALDH1A1 1665/4885KDM4E 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.